### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden

hours per response:

0.5

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

			010		veounioi			010						
1. Name and Address of Reporting Person <sup>*</sup> Meeter Dalen				2. Issuer Name and Ticker or Trading Symbol Singular Genomics Systems, Inc. [OMIC]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
				<u></u>						Director	10% C			
(Last)	(First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 08/09/2024						Officer (give title Other (specify below) below) Chief Financial Officer				
3010 SCIENCE PARK ROAD				4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable				
(Street) SAN DIEGO	СА							Line)	Form filed by On Form filed by Mo Person					
(City)	City) (State) (Zip) Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intervised at statisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										ded to			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned														
Date			2. Transaction Date (Month/Day/Yea	r) 2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)			Acquired (D) (Instr	(A) or . 3, 4 and	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	Amount (A) or (D) Pr		Price	Transaction(s) (Instr. 3 and 4)				
Common Stock 0			08/09/2024		<b>M</b> <sup>(1)</sup>		500	A	(1)	7,984 <sup>(2)</sup>	D			

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	(3)	08/09/2024		М			500	(4)	(4)	Common Stock	500	(3)	7,000	D	

Explanation of Responses:

1. Represents shares of Common Stock issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 2. On June 26, 2024, the Issuer effected a 1-for-30 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the

Reverse Stock Split.

3. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

4. The RSUs vest in 16 equal quarterly installments over four years measured from February 9, 2024.

#### /s/ Dalen Meeter

\*\* Signature of Reporting Person

08/13/2024

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.